Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study Of Radiation Therapy Plus Low Dose Temozolomide Followed By Temozolomide Plus Irinotecan For Glioblastoma Multiforme

NCT00099125 is registered in ClinicalTrials.gov with Radiation Therapy Oncology Group as lead sponsor.

NCT NCT00099125
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00099125 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study Of Radiation Therapy Plus Low Dose Temozolomide Followed By Temozolomide Plus Irinotecan For Glioblastoma Multiforme
Lead sponsor
Radiation Therapy Oncology Group
Phase
Phase 2
Overall status
Completed
Start date
November 30, 2004
Completion date
November 30, 2013
Enrollment
170 (actual)
Sites
118

Conditions

As the registry lists them; a condition with its own page is linked.

brain and central nervous system tumors